NCT00563732 is a Phase 1 clinical trial of Lecozotan in Alzheimer Disease, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Who is sponsoring NCT00563732?

NCT00563732 is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

What drugs are being tested in NCT00563732?

Interventions in NCT00563732: Lecozotan.

What condition does NCT00563732 study?

NCT00563732 studies Alzheimer Disease.

Is NCT00563732 still recruiting?

NCT00563732 is currently completed. Last updated 8 September 2008.

Last reviewed 2008-09-08 · How we verify

NCT00563732

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-Label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Lecozotan SR and a Single Oral Dose of Digoxin When Administered Orally to Healthy Adult Subjects

Completed Phase 1 Last updated 8 September 2008

What this trial tests

Phase 1 trial testing Lecozotan in Alzheimer Disease. Completed in 1 September 2008.

Timeline

1 December 2007

Primary endpoint
1 September 2008

1 September 2008

Quick facts

Lead sponsor	Wyeth is now a wholly owned subsidiary of Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 December 2007
Primary completion	1 September 2008
Estimated completion	1 September 2008

Drugs / interventions tested

Lecozotan — full drug profile →

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer — full company profile →

Who can join

Adults 18 to 55, any sex, with Alzheimer Disease. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Evaluation of the effects of multiple doses of lecozotan SR on the PK profile of a single dose of digoxin in healthy adult subjects

Sponsor's own description

Primary: To evaluate the effects of multiple doses of lecozotan SR on the PK profile of a single dose of digoxin in healthy adult subjects. Secondary: To assess the safety and tolerability of the coadministration of lecozotan SR and digoxin.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neuropathological stage-dependent proteome mapping of the olfactory tract in Alzheimer's disease: From early olfactory-related omics signatures to computational repurposing of drug candidates.
Cartas-Cejudo P, Cortés A, Lachén-Montes M, Anaya-Cubero E, et al · · 2024 · cited 4× · PMID 38454090 · DOI 10.1111/bpa.13252

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Wyeth is now a wholly owned subsidiary of Pfizer trials

Trials by the same sponsor.

NCT00909688 — Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses · Phase 1 · completed
NCT00853749 — Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine · Phase 3 · completed
NCT00894634 — Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed
NCT00854009 — Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects · Phase 1 · completed
NCT00837837 — Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00563732 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wyeth is now a wholly owned subsidiary of Pfizer
Last refreshed: 8 September 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00563732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing